Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms

Immunology Letters

Volumn 155, Issue 1-2, 2013, Pages 27-30

  Introna, M ^a   Golay, J ^a   Rambaldi, A ^a  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

Cytokine Induced Killer (CIK) cells; Haematologic neoplasms; Hematopoietic stem cells transplantation

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CYTOKINE INDUCED KILLER CELL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IN VIVO STUDY; LEUKEMIA RELAPSE; LYMPHOCYTE HOMING; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

CYTOKINE INDUCED KILLER (CIK) CELLS; HAEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS TRANSPLANTATION;

ANIMALS; ANTIGENS, CD56; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL;

EID: 84887827193     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.09.017     Document Type: Review

References (43)

1. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991, 174:139.
2. Crossland K.D., Lee V.K., Chen W., Riddell S.R., Greenberg P.D., Cheever M.A. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 1991, 146:4414.
3. Lu P.H., Negrin R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994, 153:1687.
4. Pievani A., Borleri G., Pende D., Moretta L., Rambaldi A., Golay J., et al. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118:3301.
5. Verneris M.R., Karami M., Baker J., Jayaswal A., Negrin R.S. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004, 103:3065.
6. Franceschetti M., Pievani A., Borleri G., Vago L., Fleischhauer K., Golay J., et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009, 37:616.
7. Karimi M., Cao T.M., Baker J.A., Verneris M.R., Soares L., Negrin R.S. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol 2005, 175:7819.
8. Introna M., Franceschetti M., Ciocca A., Borleri G., Conti E., Golay J., et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 2006, 38:621.
9. Introna M., Pievani A., Borleri G., Capelli C., Algarotti A., Mico C., et al. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant 2010, 16:1603.
10. Niu Q., Wang W., Li Y., Qin S., Wang Y., Wan G., et al. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 2011, 11:449.
11. Rettinger E., Kuci S., Naumann I., Becker P., Kreyenberg H., Anzaghe M., et al. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 2012, 14:91.
12. Sweeney T.J., Mailander V., Tucker A.A., Olomu A.B., Zhang W., Cao Y., et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A 1999, 96:12044.
13. Thorne S.H., Negrin R.S., Contag C.H. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006, 311:1780.
14. Edinger M., Cao Y.A., Verneris M.R., Bachmann M.H., Contag C.H., Negrin R.S. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003, 101:640.
15. Liu C., Suksanpaisan L., Chen Y.W., Russell S.J., Peng K.W. Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp Hematol 2013, 41:508.
16. Yang Z., Zhang Q., Xu K., Shan J., Shen J., Liu L., et al. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. PLoS One 2012, 7:e44802.
17. Hoyle C., Bangs C.D., Chang P., Kamel O., Mehta B., Negrin R.S. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998, 92:3318.
18. Verneris M.R., Ito M., Baker J., Arshi A., Negrin R.S., Shizuru J.A. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001, 7:532.
19. Rettinger E., Meyer V., Kreyenberg H., Volk A., Kuci S., Willasch A., et al. Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models. Front Oncol 2012, 2:32.
20. Nishimura R., Baker J., Beilhack A., Zeiser R., Olson J.A., Sega E.I., et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008, 112:2563.
21. Sconocchia G., Lau M., Provenzano M., Rezvani K., Wongsena W., Fujiwara H., et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 2005, 106:3666.
22. Schlimper C., Hombach A.A., Abken H., Schmidt-Wolf I.G. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol 2012, 238924.
23. Tettamanti S., Marin V., Pizzitola I., Magnani C.F., Giordano Attianese G.M., Cribioli E., et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol 2013, 161:389.
24. Marin V., Pizzitola I., Agostoni V., Attianese G.M., Finney H., Lawson A., et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 2010, 95:2144.
25. Kornacker M., Verneris M., Kornacker B., Ganten T., Scheffold C., Negrin R. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab. Cytotherapy 2006, 8:13.
26. Linn Y.C., Hui K.M. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma 2003, 44:1457.
27. Baker J., Verneris M.R., Ito M., Shizuru J.A., Negrin R.S. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001, 97:2923.
28. Verneris M.R., Baker J., Edinger M., Negrin R.S. Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. J Clin Immunol 2002, 22:131.
29. Jakel C.E., Hauser S., Rogenhofer S., Muller S.C., Brossart P., Schmidt-Wolf I.G. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. Clin Dev Immunol 2012, 473245.
30. Hontscha C., Borck Y., Zhou H., Messmer D., Schmidt-Wolf I.G. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011, 137:305.
31. Ma Y., Zhang Z., Tang L., Xu Y.C., Xie Z.M., Gu X.F., et al. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 2011, 14:483.
32. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2011, 2:363.
33. Leemhuis T., Wells S., Scheffold C., Edinger M., Negrin R.S. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005, 11:181.
34. Olioso P., Giancola R., Di Riti M., Contento A., Accorsi P., Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009, 27:130.
35. Linn Y.C., Yong H.X., Niam M., Lim T.J., Chu S., Choong A., et al. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy 2012, 14:851.
36. Yang B., Lu X.C., Yu R.L., Chi X.H., Liu Y., Wang Y., et al. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial. Hematol Oncol 2012, 30:115.
37. Lu X.C., Yang B., Yu R.L., Chi X.H., Tuo S., Tuo C.W., et al. Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma. Cell Biochem Biophys 2011, 62:257.
38. Wang Y., Bo J., Dai H.R., Lu X.C., Lv H.Y., Yang B., et al. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo. Exp Hematol 2013, 41:241.
39. Introna M., Borleri G., Conti E., Franceschetti M., Barbui A.M., Broady R., et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007, 92:952.
40. Laport G.G., Sheehan K., Baker J., Armstrong R., Wong R.M., Lowsky R., et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1679.
41. Linn Y.C., Niam M., Chu S., Choong A., Yong H.X., Heng K.K., et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 2012, 47:957.
42. Zhou X., Zhu J., Sun H., Shao L., Xu M., Guo H. Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting. Leuk Lymphoma 2013, 54:209.
43. Martin P.J. CIK: a path to GVL without GVHD?. Biol Blood Marrow Transplant 2011, 17:1571.